Company Overview and News

47
New Point Announces E.L. Hunsaker Appointed to the Board of Advisors

2018-06-18 globenewswire
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- New Point Exploration Corp. (CSE:NP) (OTC:NPEZF) (Frankfurt:4NP) (“New Point” or the “Company”) is pleased to announce the addition of Senior Geologist, E.L. “Buster” Hunsaker, to the Board of Advisors. “I am very excited to welcome Buster to the Advisory Board for New Point,” commented Bryn Gardener-Evans, President & CEO. “Buster was integral to the recently announced Majuba Hill Copper Project acquisition — his knowledge of this project and other quality projects in the USA will bring enormous value to the company’s portfolio.
VGZ NPEZF ABX ABCO VGZ ABX

2
VGZ / Vista Gold Corp. S-8

2018-05-18 sec.gov
SECURITIES AND EXCHANGE COMMISSION
VGZ

8
Tier Reit upgraded to overweight from neutral at J.P. Morgan

2018-05-16 marketwatch
Recent Analysis Shows Nokia, Ryman Hospitality Properties, Vista Gold, TIER REIT, Oritani Financial, and Western Gas Equity Partners, LP Market Influences -- Renewed Outlook, Key Drivers of Growth
VGZ TIER RHP VGZ WGP ORIT

1
VGZ / Vista Gold Corp. / GLOBAL STRATEGIC MANAGEMENT INC - BENEFICIAL OWNERSHIP UPDATE FOR VISTA GOLD CORP (Passive Investment)

2018-05-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Amendment NO. 6* Vista Gold Corporation ----------------------------------------------------------------------------- (Name of Issuer)
VGZ

1
VGZ / Vista Gold Corp. / GLOBAL STRATEGIC MANAGEMENT INC - BENEFICIAL OWNERSHIP UPDATE FOR VISTA GOLD CORP (Passive Investment)

2018-05-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Amendment NO. 6* Vista Gold Corporation ----------------------------------------------------------------------------- (Name of Issuer)
VGZ

6
Midas Gold Could Be Acquired For A Generous Premium In The Next 18 To 24 Months

2018-05-07 seekingalpha
There is a mineral found in Stibnite that may be a strategic asset for the U.S. in its impending trade war with China.
VGZ FNV.WT.A FNV MDRPF MAX VGZ FNV

3
Vista Gold's (VGZ) CEO Frederick Earnest on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good day, ladies and gentlemen. Welcome to Vista Gold’s First Quarter Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded. Today is Friday, May 4, 2018.
VGZ MDRPF MAX VGZ

3
Vista Gold Corp. 2018 Q1 - Results - Earnings Call Slides

2018-05-04 seekingalpha
The following slide deck was published by Vista Gold Corp. in conjunction with their 2018 Q1 earnings call.
VGZ VGZ

2
VGZ / Vista Gold Corp. 8-K (Current Report)

2018-05-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
VGZ

1
VGZ / Vista Gold Corp. FORM 8-K (Current Report)

2018-05-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
VGZ

1
VGZ / Vista Gold Corp. 10-Q (Quarterly Report)

2018-04-27 sec.gov
vgz_Current_Folio_10Q Table of Contents
VGZ

1
VGZ / Vista Gold Corp. DEFA14A

2018-03-16 sec.gov
current notice and access SCHEDULE 14A INFORMATION
VGZ

1
VGZ / Vista Gold Corp. DEF 14A

2018-03-16 sec.gov
current circular SECURITIES AND EXCHANGE COMMISSION
VGZ

1
VGZ / Vista Gold Corp. DEFA14A

2018-03-16 sec.gov
current annual return card SCHEDULE 14A INFORMATION
VGZ

1
VGZ / Vista Gold Corp. 8-K (Current Report)

2018-03-12 sec.gov
Q4 17 031218 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
VGZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to VGZ / Vista Gold Corp. on message board site Silicon Investor.

Vista Gold (VGZ) VGZ...moon shot soon?
VISTA GOLD Corp.
CUSIP: 927926303